–>
TORONTO, ONTARIO – CardioComm Solutions, Inc. (“CardioComm” or the “Company”) (TSX VENTURE:EKG) a leading global provider of consumer heart monitoring and electrocardiogram (“ECG”) acquisition and management software solutions, announced that it is seeking approval from the TSX Venture Exchange to extend the expiry dates of outstanding warrants exercisable to purchase an aggregate of 8,346,000 common shares of the Company at $0.075 per share. 7,300,000 of the warrants were issued by the Company on December 23, 2016 by way of a private placement and currently have an an expiry date of December 23, 2018. The Company is seeking to extend the expiry date of these warrants until December 23, 2020. 1,046,000 of the warrants were issued by the Company on February 3, 2017 by way of a private placement and have an an expiry date of February 3, 2019. The Company is seeking to extend the expiry date of these warrants until February 3, 2021. All other terms and conditions of the warrants remain unchanged.
To learn more about CardioComm’s products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company’s websites at www.cardiocommsolutions.com and www.theheartcheck.com.
